Now available TRAZIMERA™ (trastuzumab-qyyp)

TRAZIMERA™ is a HER2/neu receptor antagonist indicated for:

• The treatment of HER2-overexpressing breast cancer.
• The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.